CTLA4 and metastatic melanoma: Remarkable response rates in treatment of metastatic melanoma have been reported for adoptive T-cell transfer22, 23 and therapy with immune checkpoint-blocking antibodies, including anti-PD1 monotherapy2, 3 as well as anti-PD1 and anti-CTLA-4 combination therapy4, 24.